A randomized, quadruple crossover single-blind study on immediate action of Bufferin 81mg tablets and Bayaspirin 100mg in healthy volunteers

A randomized, quadruple crossover single-blind study on immediate action of Bufferin 81mg tablets and Bayaspirin 100mg in healthy volunteers - A randomized, quadruple crossover single-blind study on immediate action of Bufferin 81mg tablets and Bayaspirin 100mg in healthy volunteers

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002559

Enrollment

Registered

2009-10-01

Start date

2009-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction

Interventions

Bufferin 81mg tablets, just swallowed &gt

washout for 2 weeks &gt

Bufferin 81mg tablets, chewed and then swallowed &gt

Bayaspirin 100mg, just swallowed &gt

Bayaspirin 100mg, chewed and then swallowed Bufferin 81mg tablets, chewed and then swallowed &gt

Bayaspirin 100mg, chewed and then swallowed &gt

Bayaspirin 100mg, just swallowed Bayaspirin 100mg, just swallowed &gt

Bufferin 81mg tablets, chewed and then swallowed Bayaspirin 100mg, chewed and then swallowed &gt

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy volunteers who 1) aged 20 to 50 years, both sexes 2) exhibited normal platelet aggregation in pre-examination 3) gave their written informed consent

Exclusion criteria

Exclusion criteria: 1) history of hypersensitivity to ingredients of Bufferin 81mg tablets, Bayaspirin 100mg or salicylic acid formulation 2) history of aspirin asthma 3) use of non-steroidal anti-inflammatory drugs (NSAIDs) within past 2 weeks 4) antiplatelet agent dosed within past 2 weeks 5) anticoagulation drug dosed within past 2 weeks 6) odontectomy or other invasive operation scheduled within past 2 weeks 7) peptic ulcer disease 8) pregnancy, parturition or lactation 9) bleeding tendency 10) hypermenorrhea 11) drink alcohol on a regular basis 12) reflux esophagitis 13) other situation that doctor decides

Design outcomes

Primary

Measure	Time frame
Time-course of platelet aggregation inhibition	—

Secondary

Measure	Time frame
Time-course of plasma concentration of aspirin after oral administration, pharmacokinetic parameters (Tmax, AUC), Time-course of plasma TXB2 level	—

Countries

Japan

Contacts

Public ContactYoshimichi Sai

Kanazawa University Hospital Department of Pharmacy

sai-ys@staff.kanazawa-u.ac.jp076-265-2046

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026